Insulin Aspart: Clinical Trials

349 trials of Insulin Aspart, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

275 completed, 30 terminated, 19 unknown, 13 withdrawn. 99 Phase 4, 97 Phase 3, 65 Phase 1, 44 Not applicable, 33 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 499Completed 75, Terminated 10, Unknown 10, Withdrawn 4
Phase 397Completed 75, Terminated 17, Withdrawn 3, Active not recruiting 1, Unknown 1
Phase 165Completed 61, Unknown 3, Recruiting 1
Not applicable44Completed 30, Unknown 4, Recruiting 3, Terminated 3, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 233Completed 18, Terminated 9, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Early Phase 14Recruiting 2, Active not recruiting 1, Completed 1

Follow Insulin Aspart: new trials by email Literature Review of Insulin Aspart trials Research Report on Insulin Aspart

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection - Healthy Participants
Phase 1RecruitingGan & Lee Pharmaceuticals.262026-11-022026-11-17
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial
CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp) - Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
Not applicableNot yet recruitingHallym University502026-08-012026-07-22
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) - Type 2 Diabetes (T2DM)
Phase 2Not yet recruitingGan & Lee Pharmaceuticals.3452026-04-102026-04-15
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
I004, NovoLog - Pharmacokinetics, Pharmacodynamics
Phase 2 / Phase 3CompletedAmphastar Pharmaceuticals, Inc.622026-04-062026-07-22
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Insulin icodec, Insulin glargine, Insulin aspart - Diabetes Mellitus, Type 1
Phase 3Active not recruitingNovo Nordisk A/S8772025-08-112026-09-25
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
NNC0471-0119 H, Insulin Aspart - Diabetes Mellitus, Type 2
Phase 1CompletedNovo Nordisk A/S652025-07-112026-04-07
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
NNC0471-0119 H, Insulin aspart - Diabetes Mellitus, Type 1
Phase 1CompletedNovo Nordisk A/S432025-01-292026-09-10
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
Insulin aspart - Gestational Diabetes, Endothelial Dysfunction
Early Phase 1RecruitingAnna Stanhewicz, PhD402024-10-012026-10-29
A Trial of Three- and Seven-days Insulin Infusions Set
Mio Advanced infusions set, Novorapid, Extended wear insulin infusion (EWIS) - Type 1 Diabetes
Not applicableRecruitingSteno Diabetes Center Copenhagen802024-07-202024-08-06
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
GZR101 Injection, GZR33 Injection, Insulin aspart - Type 2 Diabetes
Phase 2UnknownGan and Lee Pharmaceuticals, USA602024-06-282024-08-19
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection - Diabetes
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.302024-05-012024-05-21
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
GZR101, insulin degledec/insulin aspart - Type 2 Diabetes
Phase 2CompletedGan and Lee Pharmaceuticals, USA1532023-11-212025-01-17
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
Acetylcholine, Insulin aspart - Gestational Diabetes, Oxidative Stress
Early Phase 1Active not recruitingAnna Stanhewicz, PhD402023-08-302026-07-29
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
Acetylcholine, insulin aspart - Gestational Diabetes, Vascular Endothelial Function
Early Phase 1RecruitingAnna Stanhewicz, PhD282023-07-012026-07-29
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
Insulin Degludec and Insulin Aspart Injection, Insulin Aspart Injection - Type 2 Diabetes Mellitus
Not applicableCompletedBeijing Hospital2182023-03-232025-12-03
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
HR011408 injection; NovoRapid®, NovoRapid®;HR011408 injection - Diabetes
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.612023-03-202024-02-07
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
Insulin Glargine, Metformin, Dapagliflozin - Insulin Pump,Continuous Glucose Monitoring Technology
Phase 4UnknownSun Yat-sen University2102023-03-072023-11-13
AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study
AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution - Diabetes Mellitus, Type 2
Phase 1CompletedArecor Limited412023-02-272024-02-16
Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects
INS062 injection, Insulin Aspart, HR20014 injection - Diabetes
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.602023-01-052023-02-09
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
I004, NovoLog - Pharmacokinetics, Pharmacodynamics
Phase 2 / Phase 3CompletedAmphastar Pharmaceuticals, Inc.692022-08-222026-03-05

Showing 20 of 349. Sign in to see all of them.

Conditions studied

Diabetes Mellitus (191)  ·  Diabetes Mellitus, Type 1 (168)  ·  Diabetes Mellitus, Type 2 (117)  ·  Insulin Resistance (33)  ·  Hypoglycemia (22)  ·  Hyperglycemia (20)  ·  Diabetes Complications (10)  ·  Diabetes, Gestational (8)  ·  Alzheimer Disease (3)  ·  Atherosclerosis (3)  ·  Cystic Fibrosis (2)  ·  Diabetic Neuropathies (2)  ·  Endocrine System Diseases (2)  ·  Glucose Intolerance (2)  ·  Glucose Metabolism Disorders (2)

Sponsors

Novo Nordisk A/S (141)  ·  Emory University (13)  ·  Florida Atlantic University (11)  ·  Sanofi (11)  ·  Halozyme Therapeutics (6)  ·  Medical University of Warsaw (6)  ·  University of Aarhus (5)  ·  Albert Einstein College of Medicine (4)  ·  Arecor Limited (4)  ·  Eli Lilly and Company (4)  ·  Karolinska Institutet (4)  ·  Mannkind Corporation (4)  ·  Medical University of Graz (4)  ·  Anna Stanhewicz, PhD (3)  ·  Institut de Recherches Cliniques de Montreal (3)

Countries

United States (135)  ·  Germany (66)  ·  France (34)  ·  Russia (33)  ·  Denmark (29)  ·  United Kingdom (29)  ·  Austria (28)  ·  Poland (26)  ·  Canada (24)  ·  Spain (21)  ·  China (19)  ·  Finland (18)  ·  India (18)  ·  Italy (17)  ·  Japan (17)

Top investigators

Betty Tuller, PhD (7)  ·  Guillermo Umpierrez, MD (4)  ·  Betty Tuller, Ph.D (3)  ·  David Baldwin, MD (3)  ·  Rubina A Heptulla, MD (3)  ·  Agnieszka Szypowska (2)  ·  Agnieszka Szypowska, Prof. (2)  ·  Bruce Buckingham, MD (2)

Results publications

PMID 28205039, PMID 30402720, PMID 23130654, PMID 24170235, PMID 26121451, PMID 26232910, PMID 26484727, PMID 35044568, PMID 24812526, PMID 25081590, PMID 28210866, PMID 28672316, PMID 29463670, PMID 30547388, PMID 36106652, PMID 37526194, PMID 40465144, PMID 41051694, PMID 42814374, PMID 10332663, PMID 11943004, PMID 12502678, PMID 15189754, PMID 15298338, PMID 15353407, PMID 15575341, PMID 16054266, PMID 16367883, PMID 16842476, PMID 17115349, PMID 17160407, PMID 17227321, PMID 17259511, PMID 17381500, PMID 17392539, PMID 17392541, PMID 17392542, PMID 17596485, PMID 17683100, PMID 17850471, PMID 17888133, PMID 17890232, PMID 17905178, PMID 17909083, PMID 17989308, PMID 18275357, PMID 18387078, PMID 18539917, PMID 18644065, PMID 18726086

NIH funding

2009 (8), 2005 (7), 2008 (7), 2014 (6), 2017 (6), 2015 (5), 2016 (4), 2004 (3), R01DK077166 (2), R01HL169201 (2), 1UC4DK108612-01 (1), F31HL177925 (1), K23DK124647 (1), K23HD103875 (1), N01HC95178 (1)